{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:07:52Z","timestamp":1792786072155,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chugoku Occupational Health Association","id":[{"id":"https:\/\/ror.org\/03b92a478","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of paclitaxel (PTX)-containing regimens, and no preventive strategy has been established. We evaluated goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), for preventing CIPN during PTX-containing chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In this open-label, randomized phase II trial across 7 institutions in Japan, patients with malignant tumors scheduled for \u22654 courses of carboplatin plus PTX (\u2265150\u2009mg\/m\u00b2) were randomized 1:1 to GJG or control, with minimization by cancer type and age. The primary endpoint was grade \u22652 CIPN incidence within 4 courses. The protocol-prespecified primary analysis used an unstratified 2-sided log-rank test (\u03b1\u2009=\u20090.10); a supportive stratified analysis accounted for the minimization factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-five patients were randomized (GJG, 32; control, 33); 52 (80.0%) had lung cancer. Grade \u22652 CIPN occurred in 28.1% (9\/32) of the GJG arm vs 51.5% (17\/33) of the control arm; the protocol-prespecified unstratified log-rank P value was .013, with a corresponding HR of 0.34 (90% CI, 0.16-0.72). In the stratified analysis accounting for cancer type and age, the estimate remained in favor of GJG but was attenuated and less precise (HR, 0.48; 90% CI, 0.22-1.02; stratified log-rank P\u2009=\u2009.101). Grade 3-5 adverse-event incidence was similar between arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GJG was associated with fewer grade \u22652 CIPN events in this predominantly lung-cancer population. Given the open-label design and uncertainty in the stratified analysis, these findings represent a phase II preventive signal warranting confirmation in a double-blind, placebo-controlled phase III trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number<\/jats:title>\n                    <jats:p>Japan Registry of Clinical Trials (jRCTs061210047).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag352","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:12:11Z","timestamp":1788520331000},"source":"Crossref","is-referenced-by-count":0,"title":["Preventive effect of goshajinkigan on paclitaxel-induced peripheral neuropathy: an open-label, randomized phase II study (OLCSG2101)"],"prefix":"10.1093","volume":"31","author":[{"given":"Takaaki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University , Okayama 700-8558,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0638-8435","authenticated-orcid":false,"given":"Go","family":"Makimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital , Okayama 700-8558,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1728-5658","authenticated-orcid":false,"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University , Okayama 700-8558,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0538-5052","authenticated-orcid":false,"given":"Yuka","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center , Ehime 791-0280,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1147","authenticated-orcid":false,"given":"Isao","family":"Oze","sequence":"additional","affiliation":[{"name":"Division of Cancer Information and Control, Aichi Cancer Center Research Institute , Nagoya 464-8681,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kurashiki Central Hospital , Okayama 710-8602,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6079-3511","authenticated-orcid":false,"given":"Shoichi","family":"Kuyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Iwakuni Clinical Center , Yamaguchi 740-8510,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-2247","authenticated-orcid":false,"given":"Satoru","family":"Senoo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Fukuyama Medical Center , Hiroshima 720-8520,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2294-1924","authenticated-orcid":false,"given":"Koji","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Ehime Prefectural Central Hospital , Ehime 790-0024,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, KKR Takamatsu Hospital , Kagawa 760-0018,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital , Okayama 700-8558,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9910-0164","authenticated-orcid":false,"given":"Yosuke","family":"Togashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital , Okayama 700-8558,","place":["Japan"]},{"name":"Department of Tumor Microenvironment, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University , Okayama 700-8558,","place":["Japan"]},{"name":"Advanced Research Field, Institute for Emerging Medical Innovation, Okayama University Hospital , Okayama 700-8558,","place":["Japan"]},{"name":"Kindai University, Faculty of Medicine , Osaka 590-0197,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Hotta","sequence":"additional","affiliation":[{"name":"Center for Innovative Clinical Medicine, Okayama University Hospital , Okayama 700-8558,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026092423220641600_oyag352-B1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.lungcan.2013.02.020","article-title":"Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer","volume":"81","author":"Satouchi","year":"2013","journal-title":"Lung Cancer"},{"key":"2026092423220641600_oyag352-B2","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026092423220641600_oyag352-B3","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"2026092423220641600_oyag352-B4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0168-8227(94)90149-x","article-title":"effects of Goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy","volume":"26","author":"Tawata","year":"1994","journal-title":"Diabetes Res Clin Pract"},{"key":"2026092423220641600_oyag352-B5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00520-017-4028-6","article-title":"Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"26","author":"Kuriyama","year":"2018","journal-title":"Support Care Cancer"},{"key":"2026092423220641600_oyag352-B6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s10147-017-1229-4","article-title":"Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"23","author":"Hoshino","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2026092423220641600_oyag352-B7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10147-015-0784-9","article-title":"Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study","volume":"20","author":"Oki","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2026092423220641600_oyag352-B8","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.7314\/APJCP.2013.14.11.6351","article-title":"The Kampo medicine Goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel","volume":"14","author":"Abe","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026092423220641600_oyag352-B9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1744-8069-10-61","article-title":"The prophylactic effects of a traditional Japanese medicine, Goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action","volume":"10","author":"Matsumura","year":"2014","journal-title":"Mol Pain"},{"key":"2026092423220641600_oyag352-B10","doi-asserted-by":"publisher","first-page":"15347354241278635","DOI":"10.1177\/15347354241278635","article-title":"Effectiveness of the traditional Japanese medicine Goshajinkigan in preventing paclitaxel-induced peripheral neuropathy: a multicenter randomized comparative trial","volume":"23","author":"Matsumura","year":"2024","journal-title":"Integr Cancer Ther"},{"key":"2026092423220641600_oyag352-B11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ygyno.2015.11.011","article-title":"Chemotherapy-induced peripheral neuropathy: current status and progress","volume":"140","author":"Brewer","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2026092423220641600_oyag352-B12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00415-005-0887-8","article-title":"Paclitaxel plus carboplatin\u2013induced peripheral neuropathy: a prospective clinical and electrophysiological study in patients suffering from solid malignancies","volume":"252","author":"Argyriou","year":"2005","journal-title":"J Neurol"},{"key":"2026092423220641600_oyag352-B13","author":"Japan Registry of Clinical Trials","year":"2026"},{"key":"2026092423220641600_oyag352-B14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.resinv.2024.07.017","article-title":"A randomized, open-label phase II study on the preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: the OLCSG2101 study protocol","volume":"62","author":"Nakamura","year":"2024","journal-title":"Respir Investig"},{"key":"2026092423220641600_oyag352-B15","author":"Tsumura & Co","year":"2026"},{"key":"2026092423220641600_oyag352-B16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/s0197-2456(96)00104-3","article-title":"A world wide web-based user interface for a data management system for use in multi-institutional clinical trials\u2014development and experimental operation of an automated patient registration and random allocation system","volume":"17","author":"Kiuchi","year":"1996","journal-title":"Control Clin Trials"},{"key":"2026092423220641600_oyag352-B17","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00520-009-0613-7","article-title":"Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02","volume":"17","author":"Shimozuma","year":"2009","journal-title":"Support Care Cancer"},{"key":"2026092423220641600_oyag352-B18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1358\/mf.1998.20.4.485687","article-title":"Effects of gosha-jinki-gan, a kampo medicine, on peripheral tissue blood flow in streptozotocin-induced diabetic rats","volume":"20","author":"Suzuki","year":"1998","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"2026092423220641600_oyag352-B19","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1007\/s00520-017-3780-y","article-title":"Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel\/carboplatin-induced peripheral neuropathy in NCCTG\/alliance clinical trials","volume":"25","author":"Le-Rademacher","year":"2017","journal-title":"Support Care Cancer"},{"key":"2026092423220641600_oyag352-B20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.breast.2020.02.011","article-title":"Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: a pilot study","volume":"51","author":"Salgado","year":"2020","journal-title":"Breast"},{"key":"2026092423220641600_oyag352-B21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/WNL.0000000000006083","article-title":"Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations","volume":"91","author":"Gewandter","year":"2018","journal-title":"Neurology"},{"key":"2026092423220641600_oyag352-B22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag352\/71151066\/oyag352.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag352\/71151066\/oyag352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag352\/71151066\/oyag352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:22:25Z","timestamp":1790306545000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag352\/8806027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag352","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,9]]},"article-number":"oyag352"}}